Search

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

She finds purpose in the saddle and pursues a passion for horses – at home and work

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

Employees join #stayhomeandfoster movement

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

She finds purpose in the saddle and pursues a passion for horses – at home and work

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Investigating MDM2-p53 in cancer

Employees join #stayhomeandfoster movement

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events